🔎 Exciting News from the Hungarian Society of Cardiology National Interventional Cardiology Congress in Debrecen, Hungary….
We have a mission!
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
Facts & Figures
> 45 countries approved registrations
> 100 shared cases on LinkedIn; > 200 reported cases
> 1.000 iVAC 2L sold
> 35 distributor agreements
> 35 hospitals use iVAC 2L on a regular base; > 7 Centers of Excellence.
> 400 patients world wide treated by iVAC 2L
> 30 publications
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
Recent newsAll news
All over the worldGrow with us!
Clinical programme supported by leading cardiologists
- Quality Engineer
Luca PorroCorporate Development
Chrisna de WetClinical & Sales Support Manager
Nikaj DroopSales & Supply Manager
Ron MalchinLogistics and Supply Chain Officer
Helena PodržajClinical & Sales Support Manager
Uwe KastenClinical & Sales Support Manager
Maja KrižajClinical & Sales Support Manager
Marleen van MastwijkEvent & Marketing Manager
Marcelo Bastos, MD MHScClinical Research Manager
Marc KlinkhamerVice President QA / RA
Naud van der VenCFO
Dr. Willem P. van LawickMember Board of Directors
Bastiaan VliegenthartManager QA / RA